Last reviewed · How we verify
FOSCARBIDOPA
Foscarbidopa works by increasing the levels of dopamine in the brain, a neurotransmitter that is often deficient in people with Parkinson's disease.
At a glance
| Generic name | FOSCARBIDOPA |
|---|---|
| Sponsor | AbbVie GK |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2024 |
Mechanism of action
Think of dopamine like a key that unlocks movement and coordination in the brain. When dopamine levels are low, as they often are in Parkinson's disease, it can be hard to move and perform everyday tasks. Foscarbidopa helps to increase dopamine levels, which can help to alleviate symptoms of Parkinson's disease.
Approved indications
- Parkinson's disease
Common side effects
- Infusion/catheter site reactions
- Infusion/catheter site infections
- Hallucinations
- Dyskinesia
Serious adverse events
- Hallucinations/Psychosis
- Infusion Site Reactions
- Infusion Site Infections
- Falling Asleep During Activities of Daily Living
- Somnolence
- Impulse Control/Compulsive Behaviors
- Withdrawal-Emergent Hyperpyrexia and Confusion
- Vitamin B6 Deficiency and Seizures
- Cardiovascular Ischemic Events
- Glaucoma
Key clinical trials
- A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa
- Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting
- Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
- Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
- A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
- Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
- Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
- Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |